Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps2-07-57 | Graves’ Disease 1 | ETA2022

Post-alemtuzumab graves’ disease remitting after switch to ocrelizumab

Popescu Veronica , Beirinckx Annemie , Decallonne Brigitte

Objectives: Graves’ hyperthyroidism is a frequent complication of alemtuzumab treatment in MS. We present the case of an MS patient who developed clinically and biochemically overt alemtuzumab-induced Graves’ disease, remitting 6 months after treatment with ocrelizumab and methylprednisolone pulse-therapy.Methods: A 49-year-old man diagnosed with active multiple sclerosis who had undergone alemtuzumab treatment, and developed Graves’ hyper...